Home ›
Marginal Zone Lymphoma Lymphoma Trials ›
NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Trial Details
NCT ID NCT06082102
Phase PHASE3
Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Status RECRUITING
Cancer Type Marginal Zone Lymphoma Lymphoma
Interventions Orelabrutinib Rituximab Lenalidomide
Locations (sample) Bengbu, Auhui, China|32.94083,117.36083 Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723 Guangzhou, Guangdong, China|23.11667,113.25 Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
Age ≥ 18 years , either sex. Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal). Prior systemic therapy including at least one anti-CD20 monoclonal antibody-containing regimen is required, with the following specifications: For combination therapies: Minimum of 2 completed treatment cycles For anti-CD20 monotherapy: Minimum of 4 administered doses Progression during tr…
For full eligibility, visit ClinicalTrials.gov .